Opinion ID: 2777754
Heading Depth: 4
Heading Rank: 6

Heading: The U.S. Attorney's Office Investigation

Text: On November 1, 2012, Abiomed disclosed that the U.S. Attorney's Office for the District of Columbia had begun an investigation into its marketing and promotional practices -15- regarding the Impella 2.5. Abiomed also maintained its Impella revenue guidance at approximately 30% for the fiscal year, despite 45% growth through the first half of the year, implying a marked slowdown during the second half of the year . . . . Minogue disclosed the FDA's compliance audit in a conference call conducted the same day and stated that Abiomed ha[d] taken extensive actions to correct [its] noted compliance issues identified in [its] annual report. Abiomed's stock price fell from $19.82 per share to $13.61 per share on November 1, a drop of approximately 32%.